36,957,681 Shares in Iovance Biotherapeutics, Inc. $IOVA Bought by BlackRock Inc.

Key Points

• BlackRock acquired 36.96 million Iovance Biotherapeutics shares in the second quarter, valued at approximately $153.7 million and representing an 8.28% stake. Institutional investors collectively own 77.03% of the company.
• Analyst sentiment is mixed but includes several bullish revisions: TD Cowen raised its price target to $10 with a Buy rating, while the average analyst target is $8.89 and the consensus rating is Hold.
• Iovance reported quarterly revenue of $198.63 million, up 65.7% year over year, and beat EPS estimates, but it remains unprofitable with a negative net margin and projected losses continuing through the forecast period.

BlackRock Inc. acquired a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 36,957,681 shares of the biotechnology company's stock, valued at approximately $153,744,000. BlackRock Inc. owned about 8.28% of Iovance Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the company. Deutsche Bank AG bought a new position in Iovance Biotherapeutics in the 2nd quarter worth $3,557,000. Rice Hall James & Associates LLC bought a new stake in Iovance Biotherapeutics during the second quarter valued at about $6,406,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Iovance Biotherapeutics during the second quarter valued at about $269,000. First National Bank & Trust Co. of Newtown purchased a new stake in Iovance Biotherapeutics in the second quarter worth about $51,000. Finally, Flputnam Investment Management Co. purchased a new stake in Iovance Biotherapeutics in the second quarter worth about $108,000. Institutional investors own 77.03% of the company's stock.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Price target raised: Iovance’s price target was increased to $10.00, implying continued upside from recent trading levels and providing a potential catalyst for the stock. Iovance Biotherapeutics Price Target Raised to $10.00
• Positive Sentiment: Some earnings revisions improved: Zacks Research raised its Iovance EPS forecasts for the third quarter of 2026, full-year 2026, second quarter of 2027, second quarter of 2028 and full-year 2028. The FY2026 loss estimate improved from $0.62 to $0.56 per share, while the FY2028 loss estimate improved from $0.10 to $0.07, suggesting expectations for better profitability over time.
• Positive Sentiment: Sector interest: Iovance was highlighted among oncology companies benefiting from continued innovation in cancer treatments. The company’s focus on cell therapy could support investor interest in its commercial and pipeline opportunities. Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
• Neutral Sentiment: Forecasts remain mixed: Zacks lowered estimates for the first quarter of 2027, third and fourth quarters of 2027, full-year 2027 and first quarter of 2028, including a reduction in the FY2027 loss forecast from $0.36 to $0.44 per share. These cuts offset several of the improved estimates.
• Negative Sentiment: Profitability remains ahead, not immediate: Zacks still expects Iovance to report losses through the forecast period, including estimated losses of $0.56 per share in FY2026 and $0.44 in FY2027. Investors therefore remain dependent on revenue growth, commercial execution and clinical progress rather than near-term profits. Zacks Industry Outlook

Analysts Set New Price Targets

IOVA has been the topic of several recent research reports. TD Cowen raised their price objective on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday, August 24th. Chardan Capital reduced their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 7th. Citigroup reissued an "outperform" rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Barclays lifted their price target on shares of Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Robert W. Baird set a $6.00 price target on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Iovance Biotherapeutics has an average rating of "Hold" and an average target price of $8.89.

Iovance Biotherapeutics Price Performance

IOVA stock opened at $8.01 on Friday. Iovance Biotherapeutics, Inc. has a 1-year low of $1.76 and a 1-year high of $9.36. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of -10.97 and a beta of 0.71. The business has a 50 day simple moving average of $5.47 and a two-hundred day simple moving average of $4.32.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. The firm had revenue of $198.63 million during the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. Iovance Biotherapeutics's revenue for the quarter was up 65.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.33) earnings per share. Sell-side analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source